



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

503. CLONAL HEMATOPOIESIS, AGING AND INFLAMMATION

Clonal Hematopoiesis Associated with Rheumatoid Arthritis

Emil Hiitola^{1,2}, Juuso Korhonen^{1,2}, Jukka Koskela³, Matti Kankainen^{1,2}, Milla Alakuijala^{1,2}, Heidi Kokkonen⁴, Aoxing Liu³, Paavo Häppölä³, Paula Savola^{2,1,5}, Tiina Kelkka^{1,2}, Marjatta Leirisalo-Repo⁶, Ritva Peltomaa⁶, Laura Pirilä⁷, Pia Isomäki⁸, Markku Kauppi^{9,10}, Oili Kaipainen-Seppänen¹¹, FinnGen Consortium¹², Giulio Genovese^{13,14,15}, Andrea Ganna³, Solbritt Rantapää-Dahlqvist¹⁶, Satu Mustjoki, MDPH^{2,17}, Mikko Myllymäki, MD, PhD^{2,1}

¹Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

²Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland

³Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

⁴Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden

⁵Department of Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

⁶Inflammation Center, Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

⁷Center for Rheumatology and Clinical Immunology, Turku University Hospital, Turku, Finland

⁸Molecular Immunology Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

⁹Päijät-Häme Central Hospital, Lahti, Finland

¹⁰Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland

¹¹Kuopio University Hospital, Kuopio, Finland

¹²University of Helsinki, Helsinki, Finland

¹³Department of Genetics, Harvard Medical School, Boston, MA

¹⁴Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA

¹⁵Stanley Center, Broad Institute of Harvard and MIT, Cambridge, MA

¹⁶Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden

¹⁷Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Introduction: Clonal hematopoiesis (CH) becomes common with age and can play a role in the pathophysiology of inflammatory diseases by modifying immune cell function. CH is characterized by the presence of somatic mutations in genes such as *DNMT3A* and *TET2* (CH of indeterminate potential, CHIP), and as mosaic chromosomal alterations (mCAs). While CHIP, particularly in the context of *TET2* mutations, can promote inflammation in cardiovascular diseases, the association between clonal hematopoiesis and autoimmunity has not been comprehensively studied to date. Rheumatoid arthritis (RA) is one of the most common autoimmune diseases primarily affecting joints. Seropositive RA is defined by the presence of anti-cyclic citrullinated peptide antibodies (ACPA) and/or rheumatoid factor (RF), whereas seronegative RA is a more heterogeneous inflammatory disease entity involving patients with clinical RA manifestations in the absence of ACPA and RF. Understanding of the association between CH and inflammatory processes may yield novel insights into prevention and management of autoimmune diseases.

Methods: To comprehensively evaluate the association between CH and autoimmune diseases, we identified CHIP variants in whole exome sequencing (WES) data from the FINRISK study (N=10 129). We also detected mCAs and CHIP in the nationwide FinnGen study (N=340 173), where we manually identified CHIP carriers as outliers in SNP intensity plots at known CHIP loci in DNA microarray data. Only known CHIP loci with variant prevalence comparable to UK Biobank WES data and significant positive associations with age and hematological malignancies were included for downstream analyses. To further characterize the link between CHIP and RA phenotypes, we performed targeted panel sequencing of 69 myeloid driver genes in 675 RA patient blood samples (91% collected at diagnosis) and 60 healthy controls. We studied the association between CH and RA

in multivariable models excluding participants with prevalent hematologic malignancies and adjusting for sex, age, smoking, and principal components of ancestry. We performed uni- and multivariable analyses to evaluate the link between CHIP and RA patient phenotypes.

Results: We identified CHIP in 381 (3.8%) FINRISK participants. As expected, the prevalence of CHIP increased with age, and CHIP variants were associated with prevalent and incident hematologic malignancies. C-reactive protein values were higher in participants with CHIP ($P < 0.001$). In multivariable models, CHIP status (OR 1.98, 1.13-3.45, $P = 0.017$) was more common in participants with questionnaire-based history of RA ($N = 151$) (Fig 1A). In the FinnGen study, CHIP carrier status was associated with prevalent autoimmune diseases (OR 1.26, 1.05-1.53, $P = 0.015$). We validated the association between prevalent RA ($N = 10,990$) and CHIP carrier status ($N = 2,393$) in the FinnGen study (OR 1.58, 1.18-2.13, $P = 0.002$) (Fig 1A). In particular, CHIP (OR 2.17, 1.40-3.36, $P < 0.001$), and *GNB1* variants (OR 4.71, 1.87-11.82, $P = 0.001$) were associated with the seronegative RA, whereas *DNMT3A* was associated with seropositive RA (OR 1.83, 1.08-3.09, $P = 0.024$). We observed no association between autosomal mCAs and RA.

Using targeted panel sequencing, we found CHIP in 22% (146/675) of RA patients. RA patients with CHIP variants were older than those without a CHIP variant (median, 69 vs 63 years, $P < 0.001$). Erythrocyte sedimentation rate (ESR) was higher in those with CHIP (median, 42.5 vs 26.0 mm/h, $P = 0.043$). RA patients with *TET2* variants were more likely to have seronegative disease compared with *TET2* wild-type patients (proportion of seronegative patients, 56% vs 33%, OR 2.62; $P = 0.008$) (Fig 1B). The association remained significant (OR 2.38, 1.14-4.96, $P = 0.02$) when adjusting for age, sex, and smoking. Evaluation of longitudinal disease outcomes by CHIP status are currently ongoing.

Conclusion: CHIP variants were more common in participants with prevalent RA in two population-level cohorts, and the association was specific to seronegative RA in the large FinnGen cohort. In newly diagnosed RA patients, *TET2* mutations were more common in seronegative than in seropositive RA. While the causality and the functional basis of these observations remain to be explored in future studies, our results provide additional evidence for the association between CHIP and inflammation in various disease contexts, including autoimmune diseases.

Disclosures Kauppi: Novartis: Membership on an entity's Board of Directors or advisory committees; UCB: Consultancy; Pfizer: Consultancy; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees. **Mustjoki:** Pfizer: Research Funding; BMS: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Dren Bio: Honoraria. **Myllymäki:** Gilead Sciences: Research Funding; Sanofi: Honoraria; Celgene: Honoraria.




Figure 1. (A) Logistic regression models for prevalent rheumatoid arthritis by CHIP status in the FINRISK study ($N = 10,129$) and in the FinnGen study ($N = 340,173$). (B) Proportion of seronegative and seropositive patients by *TET2* mutation status in newly-diagnosed RA patient cohort ($N = 616$). P value was calculated using Fisher's exact test.

Figure 1

<https://doi.org/10.1182/blood-2023-173664>